Alan S. Wayne

12.7k total citations · 5 hit papers
170 papers, 8.4k citations indexed

About

Alan S. Wayne is a scholar working on Oncology, Public Health, Environmental and Occupational Health and Hematology. According to data from OpenAlex, Alan S. Wayne has authored 170 papers receiving a total of 8.4k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Oncology, 61 papers in Public Health, Environmental and Occupational Health and 59 papers in Hematology. Recurrent topics in Alan S. Wayne's work include Acute Lymphoblastic Leukemia research (60 papers), CAR-T cell therapy research (50 papers) and Hematopoietic Stem Cell Transplantation (34 papers). Alan S. Wayne is often cited by papers focused on Acute Lymphoblastic Leukemia research (60 papers), CAR-T cell therapy research (50 papers) and Hematopoietic Stem Cell Transplantation (34 papers). Alan S. Wayne collaborates with scholars based in United States, Canada and Germany. Alan S. Wayne's co-authors include Nirali N. Shah, Maryalice Stetler‐Stevenson, Constance M. Yuan, Ira Pastan, Seth M. Steinberg, Rimas J. Orentas, Terry J. Fry, Marianna Sabatino, Cindy Delbrook and Crystal L. Mackall and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Alan S. Wayne

166 papers receiving 8.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

2014 2.2k citations Seth M. Steinberg, Alan S. Wayne et al. profile →
Survival in Medically Treated Patients with Homozygous β-Thalassemia

1994 702 citations Alan S. Wayne et al. profile →
Long-Term Survival and Late Deaths after Allogeneic Bone Marrow Transplantation

1999 525 citations Daniel J. Weisdorf, Alan S. Wayne et al. profile →
Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia

2012 440 citations Ira Pastan, David J. FitzGerald et al. Blood profile →
Immunogenicity of CAR T cells in cancer therapy

2021 208 citations Michael A. Pulsipher, Alan S. Wayne et al. profile →

Peers

Countries citing papers authored by Alan S. Wayne

Since Specialization

Citations

This map shows the geographic impact of Alan S. Wayne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan S. Wayne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan S. Wayne more than expected).

Fields of papers citing papers by Alan S. Wayne

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan S. Wayne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan S. Wayne. The network helps show where Alan S. Wayne may publish in the future.

Co-authorship network of co-authors of Alan S. Wayne

This figure shows the co-authorship network connecting the top 25 collaborators of Alan S. Wayne. A scholar is included among the top collaborators of Alan S. Wayne based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan S. Wayne. Alan S. Wayne is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Outcomes of PLAT-02 and PLAT-03: Evaluating CD19 CAR T-Cell Therapy and CD19-expressing T-APC Support in Pediatric B-ALL 2025 ·Blood ·Colleen Annesley, Kristy Seidel, Qian Wu, Corinne Summers, Alan S. Wayne, Michael A. Pulsipher, Anurag K. Agrawal, Christopher T. Brown, Stephanie Mgebroff, Catherine Lindgren, Stephanie Rawlings-Rhea, Wenjun Huang, (unknown), Michael C. Jensen, Julie R. Park, Rebecca Gardner	2
2	Phase 1/2 Dose-Escalation/Dose-Expansion Study of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL) 2024 ·Transplantation and Cellular Therapy ·Armin Ghobadi, Ibrahim Aldoss, Shannon L. Maude, Deepa Bhojwani, Alan S. Wayne, Ashish Bajel, (unknown), Rawan Faramand, Ryan J. Mattison, Michael P. Rettig, Kenneth Jacobs, Ouiam Bakkacha, John Muth, (unknown), (unknown), (unknown), (unknown), Matthew Cooper, Jan Davidson‐Moncada, John F. DiPersio	1
3	Feasibility and favorable responses after investigational CAR T-cell therapy for relapsed and refractory infant ALL 2024 ·Blood Advances ·Colleen Annesley, Adam J. Lamble, Corinne Summers, Michael A. Pulsipher, Alan S. Wayne, Julie Rivers, Wenjun Huang, (unknown), Qian Wu, Kristy Seidel, Stephanie Mgebroff, Christopher T. Brown, Catherine Lindgren, Julie R. Park, Michael C. Jensen, Rebecca Gardner	2
4	CD33–CD123 IF-THEN Gating Reduces Toxicity while Enhancing the Specificity and Memory Phenotype of AML-Targeting CAR-T Cells 2024 ·Blood Cancer Discovery ·Samy Jambon, (unknown), (unknown), Sakunthala Muthugounder, (unknown), (unknown), Alexandra E. Kovach, Brent L. Wood, (unknown), A. Sorana Morrissy, Deepa Bhojwani, Alan S. Wayne, Michael A. Pulsipher, Yong‐Mi Kim, Shahab Asgharzadeh, Chintan Parekh, Babak Moghimi	6
5	Nivolumab Plus 5-Azacitidine in Pediatric Relapsed/Refractory Acute Myeloid Leukemia (AML): Phase I/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium 2024 ·Cancers ·Anupam Verma, Yueh‐Yun Chi, Jemily Malvar, Adam J. Lamble, (unknown), Archana M. Agarwal, Hongtao Li, Gangning Liang, (unknown), Patrick A. Brown, Joel A. Kaplan, Eric S. Schafer, (unknown), Melinda Pauly, Bill H. Chang, Elliot Stieglitz, Alan S. Wayne, Nobuko Hijiya, Deepa Bhojwani	6
6	Results from the Phase 1 Portion of a Trial of Oral Ixazomib Combined with Chemotherapy in Relapsed/Refractory Acute Lymphoblastic Leukemia or Lymphoma in Children, Adolescents and Young Adults: A Report from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium 2023 ·Blood ·Eric S. Schafer, Yueh‐Yun Chi, Jemily Malvar, Teresa Rushing, Andrew Doan, Holly Pacenta, Reuven J. Schore, Richard Sposto, (unknown), Paul S. Gaynon, Jeffrey E. Rubnitz, Julio C. Barredo, (unknown), Melinda Pauly, Alan S. Wayne, Deepa Bhojwani, Terzah M. Horton	0
7	Real‐world experience in treating pediatric relapsed/refractory or therapy‐related myeloid malignancies with decitabine, vorinostat, and FLAG therapy based on a phase 1 study run by the TACL consortium 2022 ·Pediatric Blood & Cancer ·Eric S. Schafer, (unknown), Alexandra M. Stevens, Eunji Jo, Susan G. Hilsenbeck, Nathan Gossai, Andrew Doan, Susan I. Colace, (unknown), (unknown), Joel A. Kaplan, (unknown), Lauren Pommert, Alan S. Wayne, Deepa Bhojwani, Michael J. Burke	7
8	Modified Manufacturing Process Modulates CD19CAR T-cell Engraftment Fitness and Leukemia-Free Survival in Pediatric and Young Adult Subjects 2022 ·Cancer Immunology Research ·Francesco Ceppi, Ashley Wilson, Colleen Annesley, (unknown), Corinne Summers, Adam Brand, Kristy Seidel, Qian Wu, (unknown), Christopher Brown, Stephanie Mgebroff, Catherine Lindgren, Stephanie Rawlings-Rhea, Wenjun Huang, Michael A. Pulsipher, Alan S. Wayne, Julie R. Park, Michael C. Jensen, Rebecca Gardner	14
9	Myeloid lineage switch following chimeric antigen receptor T‐cell therapy in a patient with TCF3‐ZNF384 fusion‐positive B‐lymphoblastic leukemia 2018 ·Pediatric Blood & Cancer ·Matthew J. Oberley, Paul S. Gaynon, Deepa Bhojwani, Michael A. Pulsipher, Rebecca Gardner, Matthew Hiemenz, Jianling Ji, Jennifer Han, Maurice R.G. O’Gorman, Alan S. Wayne, Gordana Raca	60
10	The PI3Kδ Inhibitor Idelalisib Inhibits Homing in an in Vitro and in Vivo Model of B ALL 2017 ·Cancers ·(unknown), Hye Na Kim, Eun Ji Gang, (unknown), (unknown), (unknown), Sajad Khazal, (unknown), Marina Konopleva, Chintan Parekh, Deepa Bhojwani, Alan S. Wayne, Hisham Abdel‐Azim, Nora Heisterkamp, Yong‐Mi Kim	13
11	The American Society of Pediatric Hematology/Oncology workforce assessment: Part 1—Current state of the workforce 2017 ·Pediatric Blood & Cancer ·Jeffrey D. Hord, Mona D. Shah, Sherif M. Badawy, Dana C. Matthews, Joanne M. Hilden, Alan S. Wayne, Edward Salsberg, Patrick J. Leavey, (unknown)	23
12	The American Society of Pediatric Hematology/Oncology workforce assessment: Part 2—Implications for fellowship training 2017 ·Pediatric Blood & Cancer ·Patrick J. Leavey, Joanne M. Hilden, Dana C. Matthews, Christopher E. Dandoy, Sherif M. Badawy, Manish N. Shah, Alan S. Wayne, Jeffrey D. Hord, (unknown)	15
13	Wide Variability in the Time Required for Immunotoxins to Kill B Lineage Acute Lymphoblastic Leukemia Cells: Implications for Trial Design 2016 ·Clinical Cancer Research ·Fabian Müller, (unknown), Xiu Fen Liu, Alan S. Wayne, Ira Pastan	7
14	Protein Kinase Inhibitor H89 Enhances the Activity of Pseudomonas Exotoxin A–Based Immunotoxins 2016 ·Molecular Cancer Therapeutics ·Xiufen Liu, Fabian Müller, Alan S. Wayne, Ira Pastan	10
15	Methylation of the DPH1 promoter causes immunotoxin resistance in acute lymphoblastic leukemia cell line KOPN-8 2013 ·Leukemia Research ·Xiaobo Hu, Hui Wei, Laiman Xiang, Oleg Chertov, Alan S. Wayne, Tapan K. Bera, Ira Pastan	16
16	Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy 2012 ·Proceedings of the National Academy of Sciences ·Hui Wei, Laiman Xiang, Alan S. Wayne, Oleg Chertov, David J. FitzGerald, Tapan K. Bera, Ira Pastan	42
17	Restricted Cell Surface Expression of Receptor Tyrosine Kinase ROR1 in Pediatric B-Lineage Acute Lymphoblastic Leukemia Suggests Targetability with Therapeutic Monoclonal Antibodies 2012 ·PLoS ONE ·Hema Dave, Miriam R. Anver, Donna Butcher, Patrick O. Brown, Javed Khan, Alan S. Wayne, Sivasubramanian Baskar, Christoph Rader	40
18	National Cancer Institute’s First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Summary and Recommendations from the Organizing Committee 2011 ·Biology of Blood and Marrow Transplantation ·Michael Bishop, Edwin P. Alyea, Mitchell S. Cairo, J.H. Frederik Falkenburg, Carl H. June, Nicolaus Kröger, Richard F. Little, Jeffrey S. Miller, Steven Z. Pavletic, David Porter, Stanley R. Riddell, Koen van Besien, Alan S. Wayne, Daniel J. Weisdorf, Roy S. Wu, Sergio Giralt	31
19	The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma 2010 ·Blood ·Kieron Dunleavy, Richard F. Little, Stefania Pittaluga, Nicole Grant, Alan S. Wayne, Jorge A. Carrasquillo, Seth M. Steinberg, Robert Yarchoan, Elaine S. Jaffe, Wyndham H. Wilson	123
20	Pediatric large‐volume leukapheresis: a single institution experience with heparin versus citrate‐based anticoagulant regimens 2004 ·Transfusion ·Charles D. Bolan, Yu Ying Yau, (unknown), Mitchell E. Horwitz, Crystal L. Mackall, A. John Barrett, Harry L. Malech, Nadja N. Rehak, Alan S. Wayne, Susan F. Leitman	36

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact